BioMarin Pharmaceutical vs Insmed
BMRN and INSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRN and INSM compare
Insmed is the larger company, worth 2.2 times as much as BioMarin Pharmaceutical ($24.6B against $11.3B).
Insmed grew revenue faster over the last twelve months (240% versus 11.2% for BioMarin Pharmaceutical).
BioMarin Pharmaceutical keeps more of each dollar of sales as profit, with a net margin of 2.1% compared with −39.9% at Insmed.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRN | INSM |
|---|---|---|
| Size and price | ||
| Market cap | $11.3B | $24.6B |
| Share price | $58.51 | $112.58 |
| Change, 1 year | 12.8% | −32.6% |
| Change, 5 years | −30.3% | 237% |
| Beta (5Y) | 0.59 | 0.79 |
| Employees | 3,221 | 1,664 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 2 | 2 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 154× | – |
| P/S | 3.3× (better) | 16.2× |
| P/B | 1.8× (better) | 33.9× |
| EV/EBITDA | 48.4× | – |
| P/FCF | 15.3× | – |
| PEG | 4.54 | – |
| FCF yield | 6.5% (better) | −2.6% |
| Fair value | $23.86 | $61.67 |
| Margin of safety | −145% | −82.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.2% | 240% (better) |
| Revenue growth, 5Y average | 11.6% | 29.8% (better) |
| Net income growth (TTM) | −88.9% | – |
| EPS growth (TTM) | −88.7% | – |
| EPS growth, 5Y average | −16.7% | – |
| Profitability | ||
| Gross margin | 76.1% | 84.4% (better) |
| Operating margin | 4.4% (better) | −37.1% |
| Net margin | 2.1% (better) | −39.9% |
| FCF margin | 21.7% (better) | −41.3% |
| Return on equity | 1.2% (better) | −72.5% |
| Return on invested capital | 1.0% | – |
| Financial health | ||
| Debt / equity | 0.66 (better) | 0.76 |
| Net debt / EBITDA | 10.96 | – |
| Interest coverage | 2.0× (better) | −6.9× |
| Current ratio | 2.39 | 2.86 (better) |
| Altman Z-score | 1.86 | 6.56 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 101% | 103% |
| Held by insiders | 0.53% | 0.88% |
| Insider net buying, 12 months | −$4.3M (better) | −$167M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 6.0% | 6.4% |
Go deeper
- BMRN stock overview
- BMRN income statement
- BMRN valuation and score
- INSM stock overview
- INSM income statement
- INSM valuation and score
Other comparisons
- ALNY vs BMRN
- ALNY vs INSM
- BBIO vs INSM
- BMRN vs UTHR
- INSM vs IONS
- INSM vs JAZZ
- INSM vs KNSA
- INSM vs MDGL
- INSM vs RPRX
- INSM vs UTHR
For information only, not investment advice. Check the source filings before relying on any figure.